- Home
- INSM
INSM
Insmed Incorporated
as 05-30-2025 4:00pm EST
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 12.6B | IPO Year: | 2000 |
| Target Price: | $95.93 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $53.69 - $84.91 | Next Earning Date: | 05-08-2025 |
| Revenue: | $381,030,000 | Revenue Growth: | 20.77% |
| Revenue Growth (this year): | 29.15% | Revenue Growth (next year): | 115.02% |
Stock Insider Trading Activity of Insmed Incorporated (INSM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Flammer Martina M.D. | INSM | Chief Medical Officer | May 15 '25 | Sell | $66.50 | 11,724 | $771,276.22 | 86,596 | |
| Lewis William | INSM | Chair and CEO | May 1 '25 | Sell | $72.51 | 6,830 | $495,667.74 | 233,924 | |
| Lewis William | INSM | Chair and CEO | Apr 15 '25 | Sell | $70.49 | 6,830 | $479,176.92 | 233,924 | |
| Lewis William | INSM | Chair and CEO | Apr 1 '25 | Sell | $73.94 | 6,830 | $502,577.03 | 233,924 | |
| Lewis William | INSM | Chair and CEO | Mar 17 '25 | Sell | $76.90 | 25,580 | $1,970,420.71 | 233,924 | |
| Lewis William | INSM | Chair and CEO | Mar 3 '25 | Sell | $78.70 | 25,580 | $1,989,796.50 | 233,924 |
Latest Insmed Incorporated News
INSM Breaking Stock News: Dive into INSM Ticker-Specific Updates for Smart Investing
PR Newswire
4 days ago
Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference
MT Newswires
9 days ago
Insmed Insider Sold Shares Worth $1,886,957, According to a Recent SEC Filing
MT Newswires
10 days ago
Insmed Says Brensocatib Showed Consistent Efficacy in Non-Cystic Fibrosis Bronchiectasis
PR Newswire
10 days ago
Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study
MT Newswires
16 days ago
Insmed Insider Sold Shares Worth $633,654, According to a Recent SEC Filing
MT Newswires
16 days ago
Insmed Insider Sold Shares Worth $708,681, According to a Recent SEC Filing
Insider Monkey
18 days ago
Insmed Incorporated (INSM): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying
Zacks
18 days ago
Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and Prospects
Compare INSM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INSM Insmed Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.